Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Endovia Health Sciences, Inc.SBEV · Entity 8508 | Chief Financial Officer | April 24, 2024 | May 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Endovia Health Sciences, Inc.
Report date April 24, 2024 · Filed May 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2034-04-26 | Direct | 750,000 |
Reported balance
After 2024-04-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-26 · Grant · Acquired 750,000 · Balance 750,000 F1: The options are being issued in connection with appointment as the chief financial officer of the Company, pursuant to the 2020 Long-Term Incentive Compensation Plan. 250,000 of the options vested on April 24, 2024, with the remaining options vesting in two equal annual installments beginning on April 24, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The options are being issued in connection with appointment as the chief financial officer of the Company, pursuant to the 2020 Long-Term Incentive Compensation Plan. 250,000 of the options vested on April 24, 2024, with the remaining options vesting in two equal annual installments beginning on April 24, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2024 Filed May 6, 2024 18:22 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantStock options · Derivative | 750,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001731122-24-000741 · ownership.xml · derivative · entry 1 Ivancsits Julius Paul · CIK 0002022414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common stock · 750,000 shares Expires 2034-04-26 F1 · derivative.exercise_date: The options are being issued in connection with appointment as the chief financial officer of the Company, pursuant to the 2020 Long-Term Incentive Compensation Plan. 250,000 of the options vested on April 24, 2024, with the remaining options vesting in two equal annual installments beginning on April 24, 2025. F1 · balance_after: The options are being issued in connection with appointment as the chief financial officer of the Company, pursuant to the 2020 Long-Term Incentive Compensation Plan. 250,000 of the options vested on April 24, 2024, with the remaining options vesting in two equal annual installments beginning on April 24, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.